Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 15/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296197 | 0.89 | ENPP2 (0.49) | HDAC6ENPP2 | |
| SCHEMBL30202377 | 0.89 | ENPP2 (0.49) | HDAC6ENPP2 | |
| Hydrochloric Acid SCHEMBL1921111 | 0.88 | ENPP2 (0.49) | HDAC6ENPP2 | |
| SCHEMBL3056004 | 0.85 | ENPP2 (0.47) | HDAC6ENPP2 | |
| SCHEMBL1919522 | 0.77 | ENPP2 (0.44) | ENPP2IDO1TDO2IDO2 | |
| SCHEMBL18130455 | 0.73 | ENPP2 (0.67) | ENPP2 | |
| SCHEMBL25067211 | 0.71 | ENPP2 (0.55) | ENPP2 | |
| SCHEMBL30828230 | 0.70 | ESR2 (0.56) | IDO1TDO2IDO2 | |
| SCHEMBL1920629 | 0.70 | CYP3A4 (0.45) | HTR1AIDO1TDO2IDO2 | |
| SCHEMBL27194405 | 0.70 | ESR2 (0.56) | IDO1TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | claimed |
| EP-2326666-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-06-01 | — | — | EP | claimed |
| WO-2010031707-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | claimed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | claimed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2326666-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010031707-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | DANHO WALEED | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069307-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | NPY2R, NPY1R, NPY4R | HDAC6 2822/4885ENPP2 382/4885HTR1A 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.